Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-13T02:24:59.123Z Has data issue: false hasContentIssue false
  • English
  • Français

Successful outcomes using Long Acting Buprenorphine (LAB - Buvidal) to treat Codeine, Tramadol and other Opioid Analgesia Dependencies (OAD) in Wales during the Pandemic

Published online by Cambridge University Press:  01 September 2022

J. Melichar ,
F. Graver ,
L. Parimelalagan  and
J. Lewis
J. Melichar*
Affiliation:
University of South Wales, Health, Sport & Professonal Practice, Cardiff, United Kingdom Bath University, Pharmacy & Pharmacology, Bath, United Kingdom Cardiff and Vale University Health Board, Community Addiction Unit, Cardiff, United Kingdom
F. Graver
Affiliation:
Betsi Cadwaladr University Health Board, Community Drugs And Alcohol Services, Rhyl, United Kingdom
L. Parimelalagan
Affiliation:
Betsi Cadwaladr University Health Board, Community Drugs And Alcohol Services, Rhyl, United Kingdom
J. Lewis
Affiliation:
University of South Wales, Health, Sport & Professonal Practice, Cardiff, United Kingdom Aneurin Bevan University Health Board, Community Drugs And Alcohol Services, Newport, United Kingdom
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Long Acting Buprenorphine (LAB) – Buvidal (CAM2038) – is a prolonged release treatment for opioid dependence in adults. Its extensive use was funded by Welsh Government during the pandemic in Wales and it has been found to be a significantly better than oral medications in improving quality of life, possibly through providing allostatic craving and anxiety reduction

Objectives

This is a case series of 10 patients who were referred to Community Addiction Services in North and South West Wales with OAD.

Methods

Patients were mainly using Codeine or Tramadol and were referred due to either ongoing illicit use or via primary care services requesting support. As part of the pandemic initiative, they were initiated on Buvidal and followed up.

Results

All ten patients successfully started on Buvidal without significant issues. As a group, if transferred straight to Buvidal, they tended to have fewer significant withdrawal symptoms prior to starting on the Buvidal compared to those on Methadone or Heroin. They were treated on the usual range of Buvidal doses (1 on 64mg, the others on 96-128mg monthly). They have all stabilised and successfully moved on with their lives on Buvidal. One has used the time on Buvidal to have psychological input around past traumas and successfully detoxified in the community using Buvidal.

Conclusions

Recommendations for services considering OAD - it is a surprisingly effective treatment which is easy to start. It has the scope for being both an effective OAD recovery medication and a potentially simple detoxification strategy for this patient group.

Disclosure

Professor Melichar has provided consultancy work, presentations, training and chaired panel discussions for all the companies in this area in the UK and some outside the UK. Recent work includes Althea (UK), Britannia (UK), Camurus (UK and Global), Martin

Keywords

buprenorphinebuvidalpainlong acting
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S336
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.